WED 063 Eslicarbazepine acetate switch from carbamazepine or oxcarbazepine

Simple item page
AudienciaPúblico en generales_ES
CoberturaMéxicoes_ES
Fecha de ingreso2026-09-15T00:32:11Z
Fecha de publicación2018-01-01
ResumenPurposeTo investigate eslicarbazapine acetate (ESL) in patients transitioning from carbamazepine or oxcarbazepine in clinical practice.MethodEuro-Esli was a pooled analysis of 14 European studies. Data were analysed for patients transitioning from carbamazepine and oxcarbazepine to ESL due to lack of efficacy or poor tolerability. Responder rate (≥50% seizure frequency reduction) and seizure freedom rate (seizure freedom at least since prior visit) were assessed after 3, 6 and 12 months of ESL treatment, and at last visit. Safety/tolerability analysis evaluated adverse events (AEs) and ESL discontinuation due to AEs.ResultsEuro-Esli included 2058 patients; 233 (11.3%) transitioned from carbamazepine and 134 (6.5%) transitioned from oxcarbazepine. After 12 months, responder and seizure freedom rates for patients transitioning from carbamazepine due to lack of efficacy (n=163) were 70.0% and 30.9%, respectively. Corresponding values for patients transitioning from oxcarbazepine due to lack of efficacy (n=90) were 57.1% and 25.0%, respectively. Among patients who transitioned from carbamazepine (n=64) and oxcarbazepine (n=61) due to poor tolerability, 26.6% and 39.5% experienced AEs; 8.3% and 6.8% discontinued ESL due to AEs, respectively.ConclusionESL may be a useful option for patients experiencing intolerable AEs or not achieving adequate control with carbamazepine or oxcarbazepine.Supported by Eisai.es_ES
Doihttps://doi.org/10.1136/jnnp-2018-abn.27es_ES
URIhttps://riuat.uat.edu.mx/handle/123456789/3681
Idiomaenes_ES
EditorialBMJes_ES
RelaciónJournal of Neurology, Neurosurgery & Psychiatryes_ES
URL relacionadohttps://doi.org/10.1136/jnnp-2018-abn.27es_ES
DerechosAcceso restringido / Suscripción (Metadatos de producción científica)es_ES
Licenciahttp://purl.org/coar/access_right/c_16eces_ES
FuenteJournal of Neurology, Neurosurgery & Psychiatry
TítuloWED 063 Eslicarbazepine acetate switch from carbamazepine or oxcarbazepinees_ES
TipoArtículoes_ES
ArbitradoHa sido Arbitradoes_ES
AutorJukka, Peltola
AutorRob, McMurray
AutorVicente, Villanueva
AutorJukka, Peltolaes_ES
AutorRob, McMurrayes_ES
AutorVicente, Villanuevaes_ES
InstituciónUniversidad Autónoma de Tamaulipas
InstituciónUniversidad Autónoma de Tamaulipases_ES
Número10es_ES
Rango de páginasA7.3-A7es_ES
URL relacionadahttps://doi.org/10.1136/jnnp-2018-abn.27
Tipo de artículoIndexado
Tipo de artículoIndexadoes_ES
Volumen89es_ES

Files

Collections

Documentación Cientifica